Mumbai-based OmniActive Health Technologies has strategically entered the burgeoning women’s health market with the introduction of Fenavari, a novel combination ingredient featuring shatavari and fenugreek. This launch is underpinned by a robust, placebo-controlled clinical trial, positioning OmniActive to capture a significant share of a sector experiencing unprecedented consumer interest and scientific validation. The ingredient, announced today, represents a significant step forward in providing natural, evidence-based solutions for women navigating the menopausal journey.
A Synergistic Blend Rooted in Tradition, Validated by Science
Fenavari is meticulously formulated to combine two botanical powerhouses: shatavari (Asparagus racemosus) and fenugreek (Trigonella foenum-graecum). Both ingredients boast a rich heritage within Ayurvedic medicine, a traditional system of medicine originating in India, where they have been historically revered for their purported benefits in supporting women’s reproductive and overall health. In recent years, these ancient remedies have transcended traditional use, gaining considerable traction within the global supplement industry as scientific research increasingly validates their efficacy.
The development of Fenavari is not merely a response to market trends; it is built upon a foundation of scientific inquiry. OmniActive Health Technologies has invested in rigorous clinical research to substantiate the benefits of this unique botanical combination. The formal announcement of Fenavari’s launch coincides with the publication of a pivotal clinical study in the esteemed journal, Women’s Health Reports. This scientific endorsement provides a crucial layer of credibility for brands seeking to incorporate Fenavari into their product lines and for healthcare professionals advising their patients.
The Science Behind Fenavari: A Detailed Look at the Formulation and Clinical Trial
Fenavari is a hydroethanolic extract, a process that utilizes a mixture of water and ethanol to extract the active compounds from the botanicals. The precise ratio employed in Fenavari is three parts shatavari roots to one part fenugreek seeds. This specific ratio is designed to optimize the synergistic effects of the key phytonutrients present in each herb. The finished extract is standardized to contain 6% Shatavarin-IV, a naturally occurring steroidal saponin found abundantly in shatavari roots, and 4% Protodioscin, another potent steroidal saponin compound identified in fenugreek seeds. These standardized levels ensure consistent potency and efficacy across batches, a critical factor for both ingredient manufacturers and finished product brands.
The clinical evidence supporting Fenavari comes from a comprehensive three-arm, randomized, placebo-controlled study conducted across multiple research centers in India. This rigorous trial design is considered the gold standard for evaluating the efficacy and safety of new interventions. The study enrolled 150 participants, all women aged between 40 and 60 years. Crucially, these women were experiencing a minimum of two daily symptoms associated with menopause or perimenopause. The symptomatology included a range of common complaints such as hot flashes, headaches, mood swings, and sleep disturbances. The participant pool was diverse, encompassing individuals with generally good health and varying body mass indexes, from slender to obese, reflecting a broad spectrum of the target demographic.
To ensure the integrity of the results, participants were instructed to maintain their usual dietary habits and exercise routines throughout the 12-week study period. This adherence to normal lifestyle parameters helps to isolate the effects of the Fenavari intervention.
The study participants were divided into three distinct groups. The first group received a daily dose of 300 mg of Fenavari. The second group was administered a higher daily dose of 500 mg of Fenavari. The third group served as the control, receiving a placebo. The duration of the intervention was 12 weeks, allowing for sufficient time to observe meaningful changes in menopausal symptoms.
The primary endpoint of the study was the mean change from baseline in the severity of menopausal symptoms, as assessed by the Menopause Rating Scale (MRS). The MRS is a well-established and standardized psychometric instrument, first developed in the 1990s, designed to quantify the subjective experience of menopausal symptoms across various domains. Secondary endpoints included assessments of sleep quality, mood states, the frequency of hot flashes and/or night sweats, and other relevant indicators of well-being.
The findings of the clinical trial were compelling. The authors of the study concluded that Fenavari demonstrated a significant improvement in menopausal symptoms across somatic, psychological, and vasomotor domains, with effects becoming apparent as early as Day 14 of the intervention. Furthermore, the ingredient was found to positively impact sleep, reduce anxiety, improve mood, and promote favorable hormonal changes. The safety profile of Fenavari was also thoroughly evaluated, with no adverse events reported during the study that could be attributed to either the 300 mg or 500 mg doses of Fenavari. This indicates a favorable safety margin for the ingredient.
Strategic Market Entry: Capitalizing on a Convergence of Trends
OmniActive Health Technologies is strategically positioning Fenavari not just as another ingredient, but as a demonstrably novel and effective solution within the women’s health landscape. Keya Shah, Senior Director of the Women’s Health Category at OmniActive, articulated this vision: "Shatavari may be trending, but both shatavari and fenugreek have a long history of use in women’s health. Fenavari harnesses the power of both botanicals in one clinically studied, integrated extract, giving brands and doctors a natural solution for the full menopausal journey." This statement highlights the company’s dual approach of leveraging historical wisdom with modern scientific validation.
The timing of Fenavari’s market entry is particularly astute, coinciding with a confluence of powerful trends driving unprecedented growth in the women’s health sector. Steve Hanson, founder and CEO of the consulting firm Nutrasocial, observed that the increased focus on perimenopause and menopause has transformed these previously underserved areas into significant market categories. "The market has been out there, but until recently, it has been latent," Hanson told SupplySide Supplement Journal. "Now, there are real options available, and female consumers are actively purchasing these products."
Hanson further elaborated on the influence of another significant trend: the growing consumer interest in adaptogenic herbs over the past decade. While ashwagandha (Withania somnifera) has been the flagship of this movement, its popularity has undeniably broadened the market’s receptivity to other adaptogenic and botanically-derived wellness solutions. "But make no mistake, this is being driven by consumer demand," he emphasized.
The Importance of Quality and Formulation Expertise
The complexities inherent in botanical ingredient formulation and standardization are well-recognized within the supplement industry. Scott Steinford, CEO of Irving, Texas-based contract manufacturer PreMark Health Sciences, underscored the value of partnering with specialized ingredient suppliers like OmniActive. "These botanicals tend to be hard to assay, and that was one of the things that played into this space in the early years when the women’s health category flew under the radar," Steinford explained.
He further emphasized the critical importance of collaboration between ingredient manufacturers and contract manufacturers to ensure optimal product development. "It’s important for the ingredient manufacturer and the contract manufacturer to be able to work together to determine proper dosing and effective formulations," Steinford stated. He noted that in the past, some botanical formulations may have suffered from suboptimal efficacy due to insufficient characterization of the raw materials. Steinford concluded by recognizing OmniActive’s commitment to quality: "OmniActive has been an excellent representative in that regard."
Broader Implications for the Women’s Health Market
The launch of Fenavari by OmniActive Health Technologies is more than just the introduction of a new ingredient; it signifies a maturing of the women’s health supplement market. The growing consumer demand, coupled with increasing scientific validation and a greater emphasis on quality and standardization from ingredient suppliers, is creating a fertile ground for innovation.
For consumers, this trend translates into access to more effective, evidence-based natural solutions to address a range of health concerns, particularly those associated with menopause and perimenopause. For supplement brands, it offers opportunities to develop differentiated products that resonate with a discerning customer base seeking natural and scientifically supported wellness options. For the broader industry, it signals a continued upward trajectory for the women’s health sector, encouraging further research and development into natural approaches to female well-being.
The strategic integration of ancient Ayurvedic knowledge with modern clinical science, as exemplified by Fenavari, is likely to set a new benchmark for ingredient development in the women’s health space. As consumer awareness and scientific understanding continue to evolve, ingredients like Fenavari, backed by robust clinical data and produced with a commitment to quality, are poised to play an increasingly vital role in supporting women’s health and wellness journeys.
About the Author
Hank Schultz serves as the Senior Editor for SupplySide Supplement Journal, bringing a wealth of experience in industry journalism. His tenure in the natural products sector follows a distinguished career in daily newspaper reporting, where he honed his skills in objective and comprehensive storytelling. Schultz’s approach is characterized by a deep understanding of the industry, a commitment to journalistic integrity, and a focus on serving the needs of the readership. He was recognized with the American Herbal Products Association (AHPA) Special Award for Journalistic Excellence in 2015. His diverse interests outside of journalism include long-distance cycling, mountain climbing, and a lifelong passion for the Green Bay Packers.
